GlassScriptPhysician profile
Crystal L Brown
NPI 1063431716
$5,370.85
in general payments reported to CMS, 2019-2025
48 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $1,035 · 2021: $825 · 2022: $676 · 2023: $648 · 2024: $798 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,155 · Long Term Medical Supply Or Device Loan: $13.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,154.98 |
| Long Term Medical Supply Or Device Loan | $13.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $900.42 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $668.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $631.04 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $547.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $299.54 | 2019-2024 | |
| Amgen INC. | $289.15 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $209.36 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.47 | 2022-2024 | |
| Impulse Dynamics (USA) INC. | $169.12 | 2024 | Optimizer |
| Janssen Pharmaceuticals, INC | $111.45 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $111.11 | 2024-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $79.10 | 2022 | |
| Xeris Pharmaceuticals, INC. | $73.85 | 2021-2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $70.22 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $69.84 | 2019-2023 | Pifeltro, Dificid, Delstrigo |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.